| ［1］ |
Charrow A, Imadojemu S, Stephen S, et al. Cutaneous manifestations of IgG4⁃related disease （RD）: a systematic review［J］. J Am Acad Dermatol, 2016,75（1）:197⁃202. doi: 10.1016/j.jaad.2016.01.046.
|
| ［2］ |
Tokura Y, Yagi H, Yanaguchi H, et al. IgG4⁃related skin disease［J］. Br J Dermatol, 2014,171（5）:959⁃967. doi: 10.1111/bjd. 13296.
|
| ［3］ |
Bennett AE, Fenske NA, Rodriguez⁃Waitkus P, et al. IgG4⁃related skin disease may have distinct systemic manifestations: a systematic review［J］. Int J Dermatol, 2016,55（11）:1184⁃1195. doi: 10.1111/ijd.13369.
|
| ［4］ |
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4⁃related disease （IgG4⁃RD）, 2011［J］. Mod Rheumatol, 2012,22（1）:21⁃30. doi: 10.1007/s10165⁃011⁃0571⁃z.
|
| ［5］ |
Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4⁃related disease［J］. Arthritis Rheumatol, 2020,72（1）:7⁃19. doi: 10.1002/art.41120.
|
| ［6］ |
Cheuk W, Yuen HK, Chu SY, et al. Lymphadenopathy of IgG4⁃related sclerosing disease［J］. Am J Surg Pathol, 2008,32（5）:671⁃681. doi: 10.1097/PAS.0b013e318157c068.
|
| ［7］ |
Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4⁃RD: a systematic review and network meta⁃analysis［J］. Rheumatology （Oxford）, 2020,59（4）:718⁃726. doi: 10.1093/rheumatology/kez380.
|
